I did well, long the stock from $10.10 and the warrants from $2.89
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
FOMEV
I invented two new words I just sent them to Webster.. Look for next years dictionary to include "Fear of Missing Electric Vehicles"....
& FOMSPAC.....
"Fear Of Missing SPAC"
I invented two new words I just sent them to Webster.. Look for next years dictionary to include "Fear of Missing Electric Vehicles"....
& FOMSPAC.....
"Fear Of Missing SPAC"
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
I didn't want to mention it out of fear of being sacrilegious....
but Gummy ofthe Day
GOD
STKL
SunOpta price target raised to $18 from $15 at Lake Street
ShotSpotter price target raised to $45 from $29 at Craig-Hallum 08:44 SSTI Craig-Hallum analyst Jeremy Hamblin raised the firm's price target on ShotSpotter to $45 from $29 and keeps a Hold rating on the shares. The analyst's industry checks indicate ShotSpotter has secured several contract renewals and new contract wins over the past few months, which have likely powered shares since mid-December. Hamblin expects ShotSpotter to deliver slight upside to consensus on Q4 revenues and profitability when they report in mid-February.
SunOpta price target raised to $18 from $15 at Lake Street
ShotSpotter price target raised to $45 from $29 at Craig-Hallum 08:44 SSTI Craig-Hallum analyst Jeremy Hamblin raised the firm's price target on ShotSpotter to $45 from $29 and keeps a Hold rating on the shares. The analyst's industry checks indicate ShotSpotter has secured several contract renewals and new contract wins over the past few months, which have likely powered shares since mid-December. Hamblin expects ShotSpotter to deliver slight upside to consensus on Q4 revenues and profitability when they report in mid-February.
FLURF)
FluroTech in discussions with healthcare system to conduct clinical trials 08:37 FLURF FluroTech announced that it is actively working and achieving major milestones as the Company prepares its application for emergency use authorization with the FDA. FluroTest is in daily discussions with a major U.S. based healthcare system and finalizing plans to conduct clinical trials. FluroTest intends to complete a comprehensive and large-scale clinical trial to obtain the requisite data on its systems performance for EUA consideration. The company will update the market as appropriate. FluroTech has accelerated the financial, regulatory and legal due diligence to complete the transaction with FluroTest shareholders to obtain 95% of the interest in FluroTest. This amalgamation is subject to TSXV conditions and approvals. FluroTech is working to ensure this process is carried out in the most efficient manner possible and will update the market as appropriate. FluroTest has been informed by its biologics supplier that the reagent pair it utilizes has been shown to detect the variant strains first emerging in the U.K. and in South Africa. FluroTest targets the nucleocapsid protein on the SARS-Cov-2 coronavirus and a majority of the mutations appearing to date are of the spike protein.The Company continues to monitor the situation closely and does not anticipate efficacy concerns with the variants that have occurred thus far.
IMMR)
Immersion and Faurecia Partner for haptic automotive technologies 08:36 IMMR Faurecia, one of the world's leading automotive technology companies and Immersion announced a multi-year license agreement, providing Faurecia with access to Immersion's haptic technologies and solutions. The agreement enables Faurecia to develop advanced, interactive haptic user interfaces with the latest innovations from Immersion. "Cars in the near future will be built with smart technology, which allows intuitive touch based interactions. This agreement with Immersion expands our technology ecosystem and illustrates our forward-thinking approach to meeting the technology needs of occupants for a connected and personalized experience," declared Edouard Da Silva, Display Global Product Line Director at Faurecia Clarion Electronics. "Haptics brings new capabilities to automotive HMIs. It enables tactile surfaces to readily respond to users and creates new opportunities for OEMs to re-imagine the user experience," said Jared Smith, Interim CEO at Immersion. "We're excited to work with Faurecia to go beyond the traditional approach to automotive HMI systems and explore new ways that we can help the driver safely interact with the car."
FluroTech in discussions with healthcare system to conduct clinical trials 08:37 FLURF FluroTech announced that it is actively working and achieving major milestones as the Company prepares its application for emergency use authorization with the FDA. FluroTest is in daily discussions with a major U.S. based healthcare system and finalizing plans to conduct clinical trials. FluroTest intends to complete a comprehensive and large-scale clinical trial to obtain the requisite data on its systems performance for EUA consideration. The company will update the market as appropriate. FluroTech has accelerated the financial, regulatory and legal due diligence to complete the transaction with FluroTest shareholders to obtain 95% of the interest in FluroTest. This amalgamation is subject to TSXV conditions and approvals. FluroTech is working to ensure this process is carried out in the most efficient manner possible and will update the market as appropriate. FluroTest has been informed by its biologics supplier that the reagent pair it utilizes has been shown to detect the variant strains first emerging in the U.K. and in South Africa. FluroTest targets the nucleocapsid protein on the SARS-Cov-2 coronavirus and a majority of the mutations appearing to date are of the spike protein.The Company continues to monitor the situation closely and does not anticipate efficacy concerns with the variants that have occurred thus far.
IMMR)
Immersion and Faurecia Partner for haptic automotive technologies 08:36 IMMR Faurecia, one of the world's leading automotive technology companies and Immersion announced a multi-year license agreement, providing Faurecia with access to Immersion's haptic technologies and solutions. The agreement enables Faurecia to develop advanced, interactive haptic user interfaces with the latest innovations from Immersion. "Cars in the near future will be built with smart technology, which allows intuitive touch based interactions. This agreement with Immersion expands our technology ecosystem and illustrates our forward-thinking approach to meeting the technology needs of occupants for a connected and personalized experience," declared Edouard Da Silva, Display Global Product Line Director at Faurecia Clarion Electronics. "Haptics brings new capabilities to automotive HMIs. It enables tactile surfaces to readily respond to users and creates new opportunities for OEMs to re-imagine the user experience," said Jared Smith, Interim CEO at Immersion. "We're excited to work with Faurecia to go beyond the traditional approach to automotive HMI systems and explore new ways that we can help the driver safely interact with the car."
SeaWorld price target raised to $47 from $37 at B. Riley Securities 08:19 SEAS B. Riley Securities analyst Eric Wold raised the firm's price target on SeaWorld to $47 from $37 and keeps a Buy rating on the shares. Wold said that given the positive attendance and season pass demand trends experienced under the limited capacity restrictions, coupled with a belief that any recently-implemented operating cost efficiencies and technology benefits are more than only short-term tailwinds, he remains optimistic that theme park companies can generate greater adjusted EBITDA verses pre-pandemic periods on the same attendance levels.
Cedar Fair price target raised to $57 from $49 at B. Riley Securities
Cedar Fair price target raised to $57 from $49 at B. Riley Securities
Mohawk Group price target raised to $37 from $16 at Roth Capital 08:14 MWK Roth Capital analyst Matt Koranda raised the firm's price target on Mohawk Group to $37 from $16 and keeps a Buy rating on the shares. The analyst notes that Mohawk has announced the acquisition of Healing Solutions and increased/introduced 2021 revenue/adjusted EBITDA guidance, which both appear highly conservative.
It's all so confusing every eighth edit in the prior Vid is a carpet but the rest....